Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
14 Septiembre 2023 - 9:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
September
2023
Commission
File Number: 001-41386
OKYO
Pharma LTD
(Exact
Name of Registrant as Specified in Its Charter)
9th
Floor
107
Cheapside
London
EC2V
6DN
(Address
of registrant’s principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K
On
September 14, 2023, OKYO Pharma LTD (the “Company”) issued this 6K announcing, the withdrawal of its proposed public
offering of ordinary shares and its termination of Freedom Capital Markets as underwriter. The decision was made in response to changing
market conditions., a copy of which is furnished as Exhibit 99.1
The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
OKYO
Pharma LTD |
|
|
|
Date:
September 14, 2023 |
By: |
/s/
Keeren Shah |
|
Name: |
Keeren
Shah |
|
Title: |
Chief
Financial Officer |
EXHIBIT
INDEX
Exhibit 99.1
OKYO Pharma Limited Announces Withdrawal of Public
Offering
LONDON and NEW YORK, September 14, 2023 — OKYO
Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused
bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar
market, today announced the withdrawal of its proposed public offering of ordinary shares and its termination of Freedom Capital
Markets as underwriter. The decision was made in response to changing market conditions.
This press release shall not constitute an offer to
sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction.
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a life sciences company, focusing
on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information,
please visit www.okyopharma.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations,
estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’
‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions
are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known
and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and
could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions
security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view
of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events
as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates
to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory authority.
Enquiries:
OKYO Pharma Limited |
|
Gary S. Jacob, Chief Executive Officer |
|
+44 (0)20 7495 2379 |
Investor Relations |
|
Paul Spencer |
|
+44 (0)20 7495 2379 |
OKYO Pharma (NASDAQ:OKYO)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
OKYO Pharma (NASDAQ:OKYO)
Gráfica de Acción Histórica
De May 2023 a May 2024